-
Journal of Biological Regulators and... 2021Radiotherapy to head and neck has always been considered as a risk factor for rehabilitation with dental implants. Nevertheless, recent data suggest that overall, 5-year... (Meta-Analysis)
Meta-Analysis
Radiotherapy to head and neck has always been considered as a risk factor for rehabilitation with dental implants. Nevertheless, recent data suggest that overall, 5-year implant survival in irradiated patients can be greater than 90%. The purpose of this review was to compare the implant survival rates of irradiated and non-radiated head and neck cancer sites, and discuss the outcomes, through a systematic review approach of prospective and retrospective studies. Electronic searches were performed in the EMBASE, Cochrane, and PubMed/Medline databases up to 2019 Dec, to identify retrospective and prospective clinical studies addressing the subject. This systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The primary variables collected from the studies were the site of tumor, age and sex of the patient, site of implant placement, radiation dosage, frequency and duration of radiotherapy, follow-up duration, implant survival and stability, hard and soft tissue changes after implant placement, any type of biological and mechanical complication, and oral health quality of life (QOL). Fifteen studies including 1097 patients and a total of 4637 implants placed in irradiated and non-irradiated sites, with a follow up duration varying from 6 to 120 months, were selected for the systematic review. The results of the quantitative synthesis suggested statistically significantly better survival rate of implants placed in nonradiated sites, as compared to irradiated sites (p<0.00001). However, the cumulative survival rates over a period of 7-10 years were reported to be comparable. Quality of life (QOL) after implant rehabilitation was not found to be significantly different between the compared groups. Due to the limited number of information, insufficient data was available to draw conclusion on peri-implant complication rate. No relationship was found between age, gender, and implant survival rates. Implant placement in irradiated sites is challenging and often warrants protocol modifications. Although statistically the survival rates at irradiated sites were lower in comparison to non-radiated sites, a strict inclusion criterion in patient selection, timing of implant placement after radiotherapy, radiation dosage and regular oral hygiene maintenance could minimize the chances of implant failure in irradiated patients.
Topics: Dental Implants; Humans; Prospective Studies; Quality of Life; Retrospective Studies; Survival Rate
PubMed: 34281302
DOI: 10.23812/21-2supp1-5 -
Dental and Medical Problems 2023Narrow-diameter dental implants (NDDIs) are suggested to be a reliable alternative to bone augmentation techniques, but the evidence regarding the feasibility of NDDIs... (Review)
Review
Narrow-diameter dental implants (NDDIs) are suggested to be a reliable alternative to bone augmentation techniques, but the evidence regarding the feasibility of NDDIs in the posterior area is limited. This review investigated the survival rates of NDDIs, as well as peri-implant clinical and radiographic parameters for fixed dental prostheses in the posterior regions in comparison with standard-diameter dental implants (SDDIs). One investigator performed an electronic search of the English literature until December 2020 in the Web of Science, PubMed, Scopus, and EMBASE databases. The focused question was: "Do narrowdiameter dental implants restoring a fixed dental prosthesis demonstrate more alveolar bone loss as compared to standard-diameter dental implants in posterior maxillary and mandibular regions?" The 9 studies selected for this review assessed a total of 498 patients (250 males and 206 females; 42 patients not described in terms of gender) aged 19-81 years, with 725 NDDIs and 260 SDDIs placed. The mean follow-up duration was 71 months (range: 12-176 months). A high survival rate of NDDIs was noticed (97.4%; range: 94.7-100%). The mean probing depth (PD) and bleeding on probing (BOP) scores ranged between 3.12 mm and 3.67 mm, and between 10.00% and 33.42%, respectively. However, the only study reporting the plaque index (PI) demonstrated a mean PI score of 1.39. The majority of the studies reported the mean marginal bone loss (MBL) scores below 1 mm. In conclusion, NDDIs appear to be a feasible treatment option in patients requiring a fixed dental prosthesis in the posterior region, since they exhibit comparable survival rates to SDDIs, as well as a clinically acceptable peri-implant clinical and radiographic tissue response.
Topics: Male; Female; Humans; Dental Implants; Follow-Up Studies; Survival Rate; Dental Prosthesis, Implant-Supported; Dental Implantation, Endosseous
PubMed: 37669472
DOI: 10.17219/dmp/140757 -
Journal of Digestive Diseases Jan 2022We aimed to describe the pattern and time trends of survival from stomach cancer worldwide from population-based cancer registers. (Review)
Review
OBJECTIVES
We aimed to describe the pattern and time trends of survival from stomach cancer worldwide from population-based cancer registers.
METHODS
A systematic search of PubMed, Web of Science, EMBASE, SEER and SinoMed for articles published up to 31 December 2020 was conducted. All eligible survival analyses of stomach cancer were collected and evaluated by countries or regions, periods, sex and age groups.
RESULTS
Our review included 76 articles on stomach cancer survival rates and found that these rates had improved globally with time, although this increase was unremarkable. The highest 5-year survival rate of 72.1% was observed in Japan (2004-2007). The 5-year relative and net survival, rates were relatively high in Korea and Japan, while they were fairly poor in Africa and India. Sex-specific survival rates were higher in women than in men in America, Europe and Oceania, whereas they were relatively low in Asia. The poorest age-specific 5-year relative and net survival rates were observed in patients aged over 75 years.
CONCLUSIONS
Over the past decades, patient prognosis of stomach cancer has gradually improved worldwide and survival rates in developed regions were higher than those in developing regions. White men and Asian women had a poorer survival than white women and Asian men. Younger patients had better survival rates than those aged over 75 years globally.
Topics: Aged; Child, Preschool; Female; Humans; Incidence; India; Male; Registries; Stomach Neoplasms; Survival Analysis; Survival Rate
PubMed: 34821032
DOI: 10.1111/1751-2980.13070 -
Asian Pacific Journal of Cancer... Sep 2023Prostate cancer (Pca) is one of the most prevalent health conditions affecting men, particularly older men, and cases have increased in recent years. (Meta-Analysis)
Meta-Analysis
UNLABELLED
Prostate cancer (Pca) is one of the most prevalent health conditions affecting men, particularly older men, and cases have increased in recent years.
OBJECTIVE
This review examined the survival rate and prognostic factors of patients with Pca in Southeast Asia (SEA).
METHODS
We conducted a systematic search of three databases (PubMed, Scopus, Web of Science) and a manual search until April 1, 2022. The selected papers were evaluated using the Newcastle-Ottawa Quality Assessment Form for Cohort Studies. The review protocol was registered with PROSPERO (CRD42022326521). Pooled prevalence rates were calculated using the programme R version 4.2.1. Heterogeneity was assessed using the I2 statistic and p-value. A narrative approach was used to describe prognostic factors. Studies were selected and finalised based on the review question. The quality of the included studies was assessed.
RESULTS
A total of 11 studies were included in this review. The 1-, 3-, 5- and 10-year survival rates of SEA Pca cases were 80.8%, 51.9%, 66.1% (range 32.1-100) and 78% (range 55.9-100), respectively. Prognostic factors for Pca were discussed in terms of sociodemographic, disease-related and treatment-related aspects. The predictors of significantly lower survival were age more than 75 years, cancer detected during transurethral resection of the prostate, Gleason score more or equal to eight, high-risk group, metastases and no adjuvant radiotherapy. A meta-analysis on the pooled HR of prostate cancer could not be performed due to the heterogeneity of prognostic factors. The pooled prevalence of localised and metastatic prostate cancer in SEA countries was 39% 95% CI [20-62] and 40% 95% CI [28-53], respectively.
CONCLUSION
The survival rate in SEA countries can be determined by prognostic factors, which can be divided into sociodemographic, disease-related and treatment-related factors. Therefore, further studies are needed to improve the understanding and treatment of Pca in the region SEA.
Topics: Male; Humans; Aged; Survival Rate; Prognosis; Southeast Asian People; Transurethral Resection of Prostate; Prostatic Neoplasms
PubMed: 37774044
DOI: 10.31557/APJCP.2023.24.9.2941 -
Heart, Lung & Circulation Apr 2018Proton pump inhibitors (PPIs) are a commonly prescribed medication that recent data has linked to an increased risk of cardiovascular morbidity and all cause morbidity.... (Review)
Review
BACKGROUND
Proton pump inhibitors (PPIs) are a commonly prescribed medication that recent data has linked to an increased risk of cardiovascular morbidity and all cause morbidity. The current study sought to perform a systematic review to investigate the link between PPIs and morbidity and mortality METHODS: A systematic review was carried out as per the PRISMA guidelines, with information databases including Pubmed, Medline, and the Cochrane Review Database. English-language studies of all types published from January 1990 to October 2016 were considered. Dichotomous analysis generating odds ratios was performed using RevMan Version 5.3.
RESULTS
Thirty-seven studies were considered, of which five directly compared the effect of PPI use on mortality and/or cardiovascular morbidity (including 22,427 patients in mortality datasets, and 354,446 patients in morbidity datasets). For patients taking PPIs, all cause mortality (OR 1.68 [95% CI 1.53-1.84], p<0.001) and rate of major cardiovascular events (OR 1.54 [95% CI 1.11-2.13], p=0.01) were significantly higher.
CONCLUSIONS
The current systematic review demonstrates that, in patients using PPIs, there was a significant increase in morbidity due to cardiovascular disease. Careful consideration should be given to the prescription of PPIs while clinical equipoise remains. Further research in the area is required.
Topics: Cardiovascular Diseases; Cause of Death; Gastroesophageal Reflux; Global Health; Humans; Morbidity; Nitric Oxide; Proton Pump Inhibitors; Survival Rate
PubMed: 29233498
DOI: 10.1016/j.hlc.2017.10.020 -
Current Opinion in Critical Care Jun 2015This review outlines knowledge on the epidemiology of out-of-hospital cardiac arrest (OHCA) internationally and the contribution that resuscitation registries make to... (Review)
Review
PURPOSE OF REVIEW
This review outlines knowledge on the epidemiology of out-of-hospital cardiac arrest (OHCA) internationally and the contribution that resuscitation registries make to OHCA research. The review focuses on recent advances in the European Cardiac Arrest Registry project, EuReCa.
RECENT FINDINGS
Although literature describing the epidemiology of OHCA has proliferated in recent years, a 2010 systematic review by Berdowski et al. remains a most important publication, allowing international comparison of OHCA incidence and outcome. Recent literature supports the view that resuscitation registers are excellent sources of data on OHCA. Notable publications describe geographic variation in incidence, improvements in survival and the utility of registers in the development of survival prediction models.
SUMMARY
Data from resuscitation registries are an invaluable source of information on the incidence, management and outcome of OHCA. Registries can be used to generate hypotheses for clinical research and registry data may even be used to facilitate clinical trials. To develop international research collaboration, registries must be based on the same dataset and definitions, and include descriptions of data collection methodologies and emergency medical service (EMS) configurations. If such standardization can be achieved, the possibility of an international resuscitation registry might be realized, leading to important OHCA research opportunities worldwide.
Topics: Cardiopulmonary Resuscitation; Europe; Global Health; Humans; Incidence; Out-of-Hospital Cardiac Arrest; Outcome and Process Assessment, Health Care; Registries; Survival Rate
PubMed: 25887301
DOI: 10.1097/MCC.0000000000000206 -
PloS One 2022Definitive evidence to guide clinical practice on the principles of surgery for retroperitoneal sarcomas (RPSs) is still lacking. This study aims to summarise the... (Meta-Analysis)
Meta-Analysis
BACKGROUND
Definitive evidence to guide clinical practice on the principles of surgery for retroperitoneal sarcomas (RPSs) is still lacking. This study aims to summarise the available evidence to assess the relative benefits and disadvantages of an aggressive surgical approach with contiguous organ resection in patients with RPS, the association between surgical resection margins and survival outcomes, and the role of surgery in recurrent RPS.
METHODS
We searched PubMed, the Cochrane Library, and EMBASE for relevant randomised trials and observational studies published from inception up to May 1, 2021. Prospective or retrospective studies, published in the English language, providing outcome data with surgical treatment in patients with RPS were selected. The primary outcome was overall survival (OS).
FINDINGS
In total, 47 articles were analysed. There were no significant differences in the rates of OS (HR: 0.93; 95% CI: 0.83-1.03; P = 0.574) and recurrence-free survival (HR: 1.00; 95% CI: 0.74-1.27; P = 0.945) between the extended resection group and the tumour resection alone group. Organ resection did not increase postoperative mortality (OR: 1.00; 95% CI: 0.55-1.81; P = 0.997) but had a relatively higher complication rate (OR: 2.24, 95% CI: 0.94-5.34; P = 0.068). OS was higher in R0 than in R1 resection (HR: 1.34; 95% CI: 1.23-1.44; P < 0.001) and in R1 resection than in R2 resection (HR: 1.86; 95% CI: 1.35-2.36; P < 0.001). OS was also higher in R2 resection than in no surgery (HR: 1.26; 95% CI: 1.07-1.45; P < 0.001), however, subgroup analysis showed that the pooled HR in the trials reporting primary RPS was similar between the two groups (HR, 1.14; 95% CI, 0.87-1.42; P = 0.42). Surgical treatment achieves a significantly higher OS rate than does conservative treatment (HR: 2.42; 95% CI: 1.21-3.64; P < 0.001) for recurrent RPS.
CONCLUSIONS
For primary RPS, curative-intent en bloc resection should be aimed, and adjacent organs with evidence of direct invasion must be resected to avoid R2 resection. For recurrent RPS, surgical resection should be considered as a priority. Incomplete resection remains to have a survival benefit in select patients with unresectable recurrent RPS.
Topics: Humans; Neoplasm Recurrence, Local; Prospective Studies; Retroperitoneal Neoplasms; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate
PubMed: 35901187
DOI: 10.1371/journal.pone.0272044 -
Cancer Treatment Reviews Mar 2022Little is known about placental and fetal metastases among pregnant women with cancer. Therefore, we conducted a systematic review to identify the clinical and... (Review)
Review
INTRODUCTION
Little is known about placental and fetal metastases among pregnant women with cancer. Therefore, we conducted a systematic review to identify the clinical and pathological characteristics, treatment trends and prognosis of this entity.
METHODS
We searched PubMed and EMBASE to identify the publications reporting on placental and fetal metastases through September 2021, according to the PRISMA statement. Cases of fetal and/or placental metastases among pregnant women diagnosed with metastatic cancer during pregnancy were eligible for this review. The collected information included the patients and tumor characteristics, treatment during pregnancy and prognosis including the pregnancy outcomes.
RESULTS
We identified 72 eligible cases among which placental and fetal metastases occurred in 61 (84.7%) and 24 cases (33.3%), respectively. Gestational melanoma and lung cancers were the main culprits of placental and fetal metastases. Two-thirds of the patients were diagnosed during the third trimester and only 2.7% have received cancer-specific therapy. The median maternal survival was 1 (95% CI 0.7-1.3) months post-partum and the one-year infant survival rate was 51.1%. The median gestational age was 28 weeks and the median infant age at diagnosis was 150 days. The most common fetal metastatic sites were the lungs (21.7%), scalp (17.4%), and liver (8.7%).
CONCLUSION
Fetal metastasis occurred mainly in patients with placental metastases of melanoma and lung cancer primaries and was associated with a dismal prognosis. Collecting cases from multiple institutions using a standardized case report form is necessary to increase our awareness of the occurrence of fetal metastases and the role of systemic therapies.
Topics: Female; Humans; Infant; Melanoma; Placenta; Pregnancy; Pregnancy Outcome; Prognosis; Survival Rate
PubMed: 35182890
DOI: 10.1016/j.ctrv.2022.102356 -
Annals of Global Health Jan 2020Prostate cancer is one of the most common health issues among men, especially older men. In recent years, incidences of prostate cancer is increasing. (Meta-Analysis)
Meta-Analysis
BACKGROUND
Prostate cancer is one of the most common health issues among men, especially older men. In recent years, incidences of prostate cancer is increasing.
OBJECTIVE
The aim of this study was to provide a comprehensive estimate of the survival of prostate cancer in Asian countries.
METHODS
We searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until June 1, 2018. The Newcastle-Ottawa Quality Assessment was used to evaluate the quality of selected papers. The review protocol was registered in PROSPERO (CRD42019117044).
RESULTS
A total of 714 titles were retrieved. Thirty-seven studies met the inclusion criteria. Based on the random-effect model one-year, five-year and ten-year survival rate of prostate cancer were 81% (95% CI 77.8-84.2), 61.9% (95% CI 59.5-64.3) and 36.2% (95% CI 9.2-63.2) respectively. Survival rates based on HDI level for five-year were 30.07, 43.43 and 70.84 percent for medium, high and very high levels, respectively.
CONCLUSION
According to the results of our study, the prostate cancer survival rate in Asian countries is relatively lower than in Europe and North America.
Topics: Asia; Carcinoma; Humans; Male; Prostatic Neoplasms; Survival Rate
PubMed: 31976303
DOI: 10.5334/aogh.2607 -
Medicina (Kaunas, Lithuania) Dec 2021: Preliminary studies emphasize the similar performance of autogenous bone blocks (AUBBs) and allogeneic bone blocks (ALBBs) in pre-implant surgery; however, most of... (Review)
Review
: Preliminary studies emphasize the similar performance of autogenous bone blocks (AUBBs) and allogeneic bone blocks (ALBBs) in pre-implant surgery; however, most of these studies include limited subjects or hold a low level of evidence. The purpose of this review is to test the hypothesis of indifferent implant survival rates (ISRs) in AUBB and ALBB and determine the impact of various material-, surgery- and patient-related confounders and predictors. : The national library of medicine (MEDLINE), Excerpta Medica database (EMBASE) and Cochrane Central Register of Controlled Trials (CENTRAL) were screened for studies reporting the ISRs of implants placed in AUBB and ALBB with ≥10 participants followed for ≥12 months from January 1995 to November 2021. The review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The risk of bias was assessed via several scoring tools, dependent on the study design. Means of sub-entities were presented as violin plots. : An electronic data search resulted in the identification of 9233 articles, of which 100 were included in the quantitative analysis. No significant difference ( 0.54) was found between the ISR of AUBB (96.23 ± 5.27%; range: 75% to 100%; 2195 subjects, 6861 implants) and that of ALBB (97.66 ± 2.68%; range: 90.1% to 100%; 1202 subjects, 3434 implants). The ISR in AUBB was increased in blocks from intraoral as compared to extraoral donor sites ( 0.0003), partially edentulous as compared to totally edentulous ( 0.0002), as well as in patients younger than 45 as compared to those older ( 0.044), cortical as compared to cortico-cancellous blocks ( 0.005) and in delayed implantations within three months as compared to immediate implantations ( 0.018). The ISR of ALBB was significantly increased in processed as compared to fresh-frozen ALBB ( 0.004), but also in horizontal as compared to vertical augmentations ( 0.009). : The present findings widely emphasize the feasibility of achieving similar ISRs with AUBB and ALBB applied for pre-implant bone grafting. ISRs were negatively affected in sub-entities linked to more extensive augmentation procedures such as bone donor site and dentition status. The inclusion and pooling of literature with a low level of evidence, the absence of randomized controlled clinical trials (RCTs) comparing AUBB and ALBB and the limited count of comparative studies with short follow-ups increases the risk of bias and complicates data interpretation. Consequently, further long-term comparative studies are needed.
Topics: Bone Transplantation; Dental Implants; Hematopoietic Stem Cell Transplantation; Humans; Mouth, Edentulous; Survival Rate; United States
PubMed: 34946333
DOI: 10.3390/medicina57121388